New hope for hard-to-treat breast cancer: Dato-DXd trial targets tumors that resist hormones

NCT ID NCT07205822

Recruiting now Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 12, 2026 · Updated 25 times

Summary

This study tests a drug called Dato-DXd in people with a common type of advanced breast cancer (HR-positive, HER2-negative) that has stopped responding to hormone therapy. The goal is to see if the drug can delay cancer growth. About 100 adults whose cancer cannot be removed by surgery or has spread to other parts of the body will take part. The study is open-label, meaning everyone receives the drug.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Research Site
WITHDRAWN

Largo, Florida, 33770, United States
Research Site
RECRUITING

Fort Wayne, Indiana, 46825, United States
Research Site
RECRUITING

Omaha, Nebraska, 68130, United States
Research Site
NOT_YET_RECRUITING

New York, New York, 10021, United States
Research Site
RECRUITING

Houston, Texas, 77024, United States
Research Site
RECRUITING

Puyallup, Washington, 98373, United States
Research Site
RECRUITING

Beijing, 100021, China
Research Site
NOT_YET_RECRUITING

Changsha, 410013, China
Research Site
RECRUITING

Guangzhou, 510060, China
Research Site
NOT_YET_RECRUITING

Linyi, 276001, China
Research Site
NOT_YET_RECRUITING

Shandong, 250117, China
Research Site
NOT_YET_RECRUITING

Wuhan, 430071, China
Research Site
NOT_YET_RECRUITING

Zhengzhou, 450008, China
Research Site
RECRUITING

Clermont-Ferrand, 63050, France
Research Site
RECRUITING

La Roche-sur-Yon, 85925, France
Research Site
RECRUITING

Montpellier, 34070, France
Research Site
RECRUITING

Paris, 75005, France
Research Site
RECRUITING

Pierre-Bénite, 69310, France
Research Site
RECRUITING

Aviano, 33081, Italy
Research Site
RECRUITING

Florence, 50134, Italy
Research Site
RECRUITING

Meldola, 47014, Italy
Research Site
RECRUITING

Milan, 20141, Italy
Research Site
RECRUITING

Naples, 80131, Italy
Research Site
NOT_YET_RECRUITING

Roma, 00168, Italy
Research Site
RECRUITING

Bukgu, 41404, South Korea
Research Site
NOT_YET_RECRUITING

Goyang-si, 410-769, South Korea
Research Site
RECRUITING

Seoul, 03080, South Korea
Research Site
RECRUITING

Seoul, 06273, South Korea
Research Site
RECRUITING

Seoul, 06351, South Korea
Research Site
RECRUITING

Seoul, 06591, South Korea
Research Site
RECRUITING

Seoul, 136705, South Korea
Research Site
RECRUITING

Seoul, 3722, South Korea
Research Site
RECRUITING

Seoul, 5505, South Korea
Research Site
NOT_YET_RECRUITING

A Coruña, 15006, Spain
Research Site
RECRUITING

Barcelona, 08035, Spain
Research Site
NOT_YET_RECRUITING

Granada, 18007, Spain
Research Site
NOT_YET_RECRUITING

Madrid, 28033, Spain
Research Site
NOT_YET_RECRUITING

Madrid, 28040, Spain
Research Site
RECRUITING

Madrid, 28040, Spain
Research Site
NOT_YET_RECRUITING

Seville, 41009, Spain
Research Site
NOT_YET_RECRUITING

Valencia, 46009, Spain

Conditions

Explore the condition pages connected to this study.

BREAST CANCER